Eli Lilly Basic EPS 2010-2024 | LLY

Eli Lilly annual/quarterly basic eps history and growth rate from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
  • Eli Lilly basic eps for the quarter ending September 30, 2024 was $1.08, a 1900% decline year-over-year.
  • Eli Lilly basic eps for the twelve months ending September 30, 2024 was $9.29, a 67.69% increase year-over-year.
  • Eli Lilly annual basic eps for 2023 was $0.006B, a 16.02% decline from 2022.
  • Eli Lilly annual basic eps for 2022 was $0.007B, a 12.68% increase from 2021.
  • Eli Lilly annual basic eps for 2021 was $0.006B, a 9.82% decline from 2020.
Eli Lilly Annual Basic EPS
2023 $5.82
2022 $6.93
2021 $6.15
2020 $6.82
2019 $8.93
2018 $3.14
2017 $-0.19
2016 $2.59
2015 $2.27
2014 $2.23
2013 $4.33
2012 $3.67
2011 $3.90
2010 $4.58
2009 $3.94
Eli Lilly Quarterly Basic EPS
2024-09-30 $1.08
2024-06-30 $3.29
2024-03-31 $2.49
2023-12-31 $2.43
2023-09-30 $-0.06
2023-06-30 $1.96
2023-03-31 $1.49
2022-12-31 $2.15
2022-09-30 $1.61
2022-06-30 $1.06
2022-03-31 $2.11
2021-12-31 $1.91
2021-09-30 $1.22
2021-06-30 $1.53
2021-03-31 $1.49
2020-12-31 $2.33
2020-09-30 $1.33
2020-06-30 $1.56
2020-03-31 $1.60
2019-12-31 $1.79
2019-09-30 $1.37
2019-06-30 $1.44
2019-03-31 $4.33
2018-12-31 $1.10
2018-09-30 $1.13
2018-06-30 $-0.25
2018-03-31 $1.16
2017-12-31 $-1.58
2017-09-30 $0.53
2017-06-30 $0.96
2017-03-31 $-0.10
2016-12-31 $0.72
2016-09-30 $0.74
2016-06-30 $0.71
2016-03-31 $0.42
2015-12-31 $0.45
2015-09-30 $0.75
2015-06-30 $0.57
2015-03-31 $0.50
2014-12-31 $0.40
2014-09-30 $0.47
2014-06-30 $0.68
2014-03-31 $0.68
2013-12-31 $0.68
2013-09-30 $1.11
2013-06-30 $1.12
2013-03-31 $1.42
2012-12-31 $0.75
2012-09-30 $1.18
2012-06-30 $0.83
2012-03-31 $0.91
2011-12-31 $0.77
2011-09-30 $1.11
2011-06-30 $1.07
2011-03-31 $0.95
2010-12-31 $1.05
2010-09-30 $1.18
2010-06-30 $1.22
2010-03-31 $1.13
2009-12-31 $0.82
2009-09-30 $0.86
2009-06-30 $1.06
2009-03-31 $1.20
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $789.394B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51